- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.05. | ImageneBio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.04. | ImageneBio $30 Million Private Placement Ignites Stock | 1 | Benzinga.com | ||
| IMAGENEBIO Aktie jetzt für 0€ handeln | |||||
| 13.04. | ImageneBio stock jumps on $30M financing | 1 | Seeking Alpha | ||
| 13.04. | ImageneBio: 30 Millionen US-Dollar für Medikament gegen Haarausfall und Dermatitis | 1 | Investing.com Deutsch | ||
| 13.04. | ImageneBio, Inc.: ImageneBio Announces $30 Million Private Placement | 1 | GlobeNewswire (USA) | ||
| 13.04. | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.03. | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 10.03. | ImageneBio, Inc. GAAP EPS of -$9.64 | 1 | Seeking Alpha | ||
| 10.03. | ImageneBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 10.03. | ImageneBio, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 10.03. | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.02. | ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer | 1 | Investing.com | ||
| 10.02. | ImageneBio, Inc.: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer | 1.046 | GlobeNewswire (Europe) | Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion... ► Artikel lesen | |
| 18.12.25 | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | ImageneBio, Inc.: ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team | 533 | GlobeNewswire (Europe) | $142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to... ► Artikel lesen | |
| 01.08.25 | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 248 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and... ► Artikel lesen | |
| 25.07.25 | Ikena Oncology, Inc.: Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million | 398 | GlobeNewswire (Europe) | The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will... ► Artikel lesen | |
| 23.07.25 | Ikena Oncology, Inc.: Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company | 333 | GlobeNewswire (Europe) | BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema... ► Artikel lesen | |
| 15.07.25 | Ikena Oncology, Inc.: Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals | 375 | GlobeNewswire (Europe) | Combined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc.... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,115 | +1,79 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| BIOGEN | 170,24 | +0,75 % | Biogen's Salanersen Wins FDA Breakthrough Therapy Designation For Spinal Muscular Atrophy Treatment | WESTON (dpa-AFX) - Thursday, Biogen Inc. (BIIB) announced that the U.S. Food and Drug Administration has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,950 | +2,57 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| ABIVAX | 88,95 | +16,05 % | Abivax mit Daten: Erst Rakete, dann Absturz - erhöht Obefazimod das Krebsrisiko? | Die Aktie von Abivax hat am Montagabend genau die Nachricht geliefert, auf die Investoren seit Monaten gewartet hatten. Das französische Biotech-Unternehmen präsentierte herausragende Topline-Ergebnisse... ► Artikel lesen | |
| LAKEFRONT BIOTHERAPEUTICS | 23,680 | +1,11 % | Lakefront Biotherapeutics: Lakefront Receives Transparency Notification from Bank of America | Mechelen, Belgium; May 26, 2026, 22.01 CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.
Pursuant to... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,765 | +6,35 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,360 | +12,21 % | Cardiff Oncology meldet positive Phase-2-Studienergebnisse für Onvansertib | ||
| CYTOKINETICS | 60,56 | -0,66 % | Cytokinetics, Incorporated: Cytokinetics bringt MYQORZO (aficamten) in der Europäischen Union auf den Markt; der erste kommerzielle Vertrieb erfolgt in Deutschland | Auf den erfolgreichen Start in den USA folgt nun die Markteinführung in Europa
SOUTH SAN FRANCISCO, Kalifornien, und ZUG, Schweiz, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,291 | +1,49 % | Aktionäre von Coherus Oncology stimmen für Direktorenwahl und Änderungen am Eigenkapital-Plan | ||
| CYTOMX THERAPEUTICS | 2,781 | 0,00 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 16,000 | +0,98 % | SelfCare Sensei, LLC: Wellbeing Educator and Martial Artist Jan Raeder Officially Launches Strive for M.O.R.E., the Book That Found 400 Readers Before It Ever Had a Launch | After three decades on the mat and a master's in wellbeing education, Raeder is done watching people settle for bubble baths when the science offers something betterPOTTERSVILLE, N.Y., June... ► Artikel lesen | |
| BIOAGE LABS | 14,130 | +2,24 % | BioAge Labs, Inc.: BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates | Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept... ► Artikel lesen | |
| REGENXBIO | 5,678 | +2,68 % | REGENXBIO Inc. - 8-K, Current Report | ||
| VANDA PHARMACEUTICALS | 5,305 | +1,24 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results | Fanapt® net product sales rose 26% to $29.6 million; total prescriptions increased 32% and new-to-brand prescriptions surged 76%
NEREUS (tradipitant) launched... ► Artikel lesen |
Das Unternehmen IMAGENEBIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,690 Euro und damit +4,40 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMAGENEBIO INC finden Sie auf Wallstreet Online.